Tradipitant

Drug Profile

Tradipitant

Alternative Names: LY-686017; VLY 686

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; National Institute on Alcohol Abuse and Alcoholism; Vanda Pharmaceuticals
  • Class Antipruritics; Anxiolytics; Chlorobenzenes; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Neurokinin 1 receptor antagonists; Substance P inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastroparesis; Pruritus
  • Discontinued Alcoholism; Social phobia

Most Recent Events

  • 29 Mar 2017 Eli lilly has patent protection for tradipitant worldwide (Vanda pharmaceuticals form 10-k, March 2017)
  • 29 Mar 2017 Eli lilly has patents pending for tradipitant worldwide (Vanda pharmaceuticals form 10-k, March 2017)
  • 01 Nov 2016 Phase-II clinical trials in Gastroparesis in USA (PO) (NCT02970968)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top